{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.5","upperLimit":"89.7","value":"75.9"},{"groupId":"OG001","lowerLimit":"18.4","upperLimit":"67.1","value":"41.2"},{"groupId":"OG002","lowerLimit":"85.1","upperLimit":"97.3","value":"92.9"},{"groupId":"OG003","lowerLimit":"86.5","upperLimit":"99.5","value":"96.1"},{"groupId":"OG004","lowerLimit":"71.8","upperLimit":"96.6","value":"87.9"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.2","upperLimit":"94.2","value":"82.8"},{"groupId":"OG001","lowerLimit":"18.4","upperLimit":"67.1","value":"41.2"},{"groupId":"OG002","lowerLimit":"86.7","upperLimit":"98.0","value":"94.0"},{"groupId":"OG003","lowerLimit":"86.5","upperLimit":"99.5","value":"96.1"},{"groupId":"OG004","lowerLimit":"75.7","upperLimit":"98.1","value":"90.9"}]}],"title":"24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"84"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"Complete Cytogenetic Response (CCyR) rate is defined as the proportion of all treated participants who achieve a CCyR while on-study. CCyR rate is defined as 0% Ph+ metaphases in at least 20 metaphases in bone marrow. The percentage of treated participants with CCyR is reported by arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 2"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG002","title":"Cohort 3"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG003","title":"Cohort 3a"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG004","title":"Cohort 3b"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"24 months","title":"Complete Cytogenetic Response (CCyR) Rate up to 2 Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}